Ipsen has expressed its disappointed regarding the National Institute for Health and Care Excellence’s (NICE) preliminary guidance which does not recommend Cabometyx – also known as cabozantinib.
The treatment involves patients with previously-treated differentiated thyroid cancer (DTC) which is unsuitable for radioactive iodine and has progressed after systemic treatment…
